Bispecific antibody News and Research

RSS

New gene signature predicts immunotherapy success for bone marrow cancers

A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and, in principle, fight cancer cells, but is often not sufficiently activated.

10 Aug 2026

QUANTUM trial tests immune-targeting approach for primary plasma cell leukemia

The Alliance for Clinical Trials in Oncology today announced the activation of The QUANTUM Trial (Alliance A062401), a clinical study designed to test a novel, immune-targeting approach for patients newly diagnosed with primary plasma cell leukemia (PCL).

30 Jul 2026

Targeted therapy doubles progression-free survival in rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

2 Jul 2026

Review outlines key strategies to overcome antibody drug conjugate resistance

The first Antibody-drug conjugate (ADC) was approved overa quarter-century ago, and today more than 20 have reached the clinic.

24 Jun 2026

Bio‑Techne and Refeyn close critical gap in bispecific antibody and biosimilar characterization

Bio‑Techne Corporation, a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first‑of‑its‑kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.

From Bio-Techne 4 Jun 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

The power of organoids in speeding up lifesaving drug development

Organoids are miniature tissue or organ models formed by stem cells (including pluripotent stem cells, tissue-specific adult stem cells, etc.) or progenitor cells in an in vitro three-dimensional culture system, which possess structural features and partial functions analogous to their corresponding in vivo organs. In 2009, the Hans Clevers laboratory developed the first intestinal organoid, marking the inception of organoid-based disease modeling.

8 May 2026

DLL3 on circulating tumor cells predicts tarlatamab success in lung cancer

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.

14 Jan 2026

Antibody therapy clears residual multiple myeloma in early trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Dec 2025

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

New trial shows major survival gains with epcoritamab added to standard R2 therapy

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

7 Dec 2025

Zanidatamab shows durable and meaningful responses in HER2-positive biliary tract cancer

Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the HERIZON-BTC-01 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

25 Nov 2025

Advances in diagnosis and management of systemic light chain amyloidosis

Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues and organs, leading to progressive structural and functional impairment.

30 Oct 2025

BioDlink Commends Junshi Biosciences as its Bispecific ADC Candidate JS212 Receives IND Approval

BioDlink, a leading global CDMO, extends its congratulations to Junshi Biosciences, on receiving Investigational New Drug (IND) approval

From BioDlink 12 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

8 Sep 2025

New AAV gene therapy reverses age-related macular degeneration

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal neovascularization and subretinal hemorrhage and exudation, leading to vision impairment. Current first-line treatment for nAMD are anti-VEGF agents, which has shown promising therapeutics outcomes.

18 Aug 2025

Bispecific antibody News and Research

New gene signature predicts immunotherapy success for bone marrow cancers

QUANTUM trial tests immune-targeting approach for primary plasma cell leukemia

Targeted therapy doubles progression-free survival in rare bile duct cancer

Review outlines key strategies to overcome antibody drug conjugate resistance

Bio‑Techne and Refeyn close critical gap in bispecific antibody and biosimilar characterization

Polymer-based immunotherapies enhance tumor targeting and immune activation

The power of organoids in speeding up lifesaving drug development

DLL3 on circulating tumor cells predicts tarlatamab success in lung cancer

Antibody therapy clears residual multiple myeloma in early trial

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Combination therapy may boost survival for people with aggressive lymphoma

New trial shows major survival gains with epcoritamab added to standard R2 therapy

Zanidatamab shows durable and meaningful responses in HER2-positive biliary tract cancer

Advances in diagnosis and management of systemic light chain amyloidosis

BioDlink Commends Junshi Biosciences as its Bispecific ADC Candidate JS212 Receives IND Approval

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

New AAV gene therapy reverses age-related macular degeneration

Emerging therapies reshape the future of AMD treatment

Early-career physician-scientists receive major support from Damon Runyon Cancer Research Foundation

New immunotherapy targets leukemia at its root

Antibodies eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News